Skip to content
The Nexus
DossierENTITY

Bristol-Myers Squibb

Coverage of Bristol-Myers Squibb in the Nexus archive.

Earliest in view: Jul 27 · 10:32 UTCMost recent: Jul 27 · 10:32 UTC
Co-mentioned in this coverage
dual immunotherapytopic1metastatic melanomatopic1
Recent coverage
  • HEALTHJul 27 · 10:32 UTCTHE HINDU NATIONAL
    BMS launches dual immunotherapy for metastatic melanoma

    Bristol-Myers Squibb (BMS) has launched a dual immunotherapy treatment for metastatic melanoma, a type of advanced skin cancer. The therapy combines two immune checkpoint inhibitors to enhance anti-tumor responses.

Bristol-Myers Squibb · Dossier · The Nexus